sales@reportocean.com (Bussiness Sales)
+18882123539 (Us - Toll Free)
+919997112116 (Rest Of World)
Insomnia Market by Therapy Type [Non-pharmacological Therapy (Hypnotherapy, Cognitive Behavioral Therapy, Medical Devices, and Other Non-pharmacological Therapy) and Pharmacological Therapy (Prescription Sleep Aids and Over-The-Counter Sleep Aids)] - Global Opportunity Analysis and Industry Forecast, 2017-2023

Insomnia Market by Therapy Type [Non-pharmacological Therapy (Hypnotherapy, Cognitive Behavioral...

Home / Categories / Healthcare
Insomnia Market by Therapy Type [Non-pharmacological Therapy (Hypnotherapy, Cognitive Behavioral Therapy, Medical Devices, and Other Non-pharmacological Therapy) and Pharmacological Therapy (Prescription Sleep Aids and Over-The-Counter Sleep Aids)] - Global Opportunity Analysis and Industry Forecast, 2017-2023
Insomnia Market by Therapy Type...
Report Code
RO1/113/1210

Publish Date
01/Jun/2017

Pages
120
PRICE
$ 1800/-
This is a single user license, allowing one specific user access to the product. The product is a PDF.
$ 2350/-
This is a 1-5 user license, allowing up to five users have access to the product. The product is a PDF.
$ 2850/-
This is an enterprise license, allowing all employees within your organization access to the product. The product is a PDF..
CHAPTER 1 INTRODUCTION

1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY

1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools & models

CHAPTER 2 EXECUTIVE SUMMARY

2.1. CXO PERSPECTIVE

CHAPTER 3 MARKET OVERVIEW

3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS

3.2.1. Top investment pockets
3.2.2. Top winning strategies

3.3. PORTERS FIVE FORCES ANALYSIS
3.4. REGULATION AND REIMBURSEMENT SCENARIO
3.5. MARKET DYNAMICS

3.5.1. Drivers

3.5.1.1. Emergence of therapeutics with fewer side-effects
3.5.1.2. Rise in demand for OTC sleep aids
3.5.1.3. Stressful work condition and working in shifts

3.5.2. Restraints

3.5.2.1. Side Effects of Drugs
3.5.2.2. Rise in number of patent expiration of branded prescription drugs

3.5.3. Opportunities

3.5.3.1. Untapped Markets in Developing Economies
3.5.3.2. Presence of Large Undiagnosed Insomnia Population Pool

CHAPTER 4 INSOMNIA MARKET, BY THERAPY TYPE

4.1. OVERVIEW

4.1.1. Market size and forecast

4.2. NON-PHARMACOLOGICAL THERAPY

4.2.1. Key market trends
4.2.2. Growth factors and opportunities
4.2.3. Market size and forecast
4.2.4. Hypnotherapy
4.2.5. Cognitive Behavioral Therapy
4.2.6. Medical Devices
4.2.7. Other Non-pharmacological Therapy

4.3. PHARMACOLOGICAL THERAPY

4.3.1. Key market trends
4.3.2. Growth factors and opportunities
4.3.3. Market size and forecast
4.3.4. Prescription sleep aids
4.3.5. Over-the-counter sleep aids

CHAPTER 5 INSOMNIA MARKET, BY GEOGRAPHY

5.1. OVERVIEW

5.1.1. Market size and forecast

5.2. NORTH AMERICA

5.2.1. Key market trends
5.2.2. Key growth factors and opportunities
5.2.3. Market size and forecast

5.2.3.1. U.S. market size and forecast
5.2.3.2. Mexico market size and forecast
5.2.3.3. Canada market size and forecast

5.3. EUROPE

5.3.1. Key market trends
5.3.2. Key growth factors and opportunities
5.3.3. Market size and forecast

5.3.3.1. UK market size and forecast
5.3.3.2. France market size and forecast
5.3.3.3. Germany market size and forecast

5.4. ASIA-PACIFIC

5.4.1. Key market trends
5.4.2. Key growth factors and opportunities
5.4.3. Market size and forecast

5.4.3.1. India market size and forecast
5.4.3.2. Japan market size and forecast
5.4.3.3. China market size and forecast
5.4.3.4. Rest of Asia-Pacific market size and forecast

5.5. LAMEA

5.5.1. Key market trends
5.5.2. Key growth factors and opportunities
5.5.3. Market size and forecast

5.5.3.1. Brazil market size and forecast
5.5.3.2. South Africa market size and forecast
5.5.3.3. Saudi Arabia market size and forecast
5.5.3.4. Rest of LAMEA market size and forecast

CHAPTER 6 COMPANY PROFILES

6.1. MERCK & CO. INC.

6.1.1. Company overview
6.1.2. Company snapshot
6.1.3. Operating business segments
6.1.4. Business performance
6.1.5. Key strategic moves and developments

6.2. SANOFI

6.2.1. Company overview
6.2.2. Company snapshot
6.2.3. Operating business segments
6.2.4. Business performance
6.2.5. Key strategic moves and developments

6.3. PFIZER, INC.

6.3.1. Company overview
6.3.2. Company snapshot
6.3.3. Operating business segments
6.3.4. Business performance
6.3.5. Key strategic moves and developments

6.4. TAKEDA PHARMACEUTICAL COMPANY LTD.

6.4.1. Company overview
6.4.2. Company snapshot
6.4.3. Operating business segments
6.4.4. Business performance
6.4.5. Key strategic moves and developments

6.5. PURDUE PHARMACEUTICALS L.P.

6.5.1. Company overview
6.5.2. Company snapshot
6.5.3. Operating business segments
6.5.4. Business performance
6.5.5. Key strategic moves and developments

6.6. EISAI, CO. LTD.

6.6.1. Company overview
6.6.2. Company snapshot
6.6.3. Operating business segments
6.6.4. Business performance
6.6.5. Key strategic moves and developments

6.7. MEDA CONSUMER HEALTHCARE INC.

6.7.1. Company overview
6.7.2. Company snapshot
6.7.3. Operating business segments
6.7.4. Business performance
6.7.5. Key strategic moves and developments

6.8. PERNIX THERAPEUTICS

6.8.1. Company overview
6.8.2. Company snapshot
6.8.3. Operating business segments
6.8.4. Business performance
6.8.5. Key strategic moves and developments

6.9. VANDA PHARMACEUTICALS

6.9.1. Company overview
6.9.2. Company snapshot
6.9.3. Operating business segments
6.9.4. Business performance
6.9.5. Key strategic moves and developments

6.10. ECR PHARMACEUTICALS

6.10.1. Company overview
6.10.2. Company snapshot
6.10.3. Operating business segments
6.10.4. Business performance
6.10.5. Key strategic moves and developments

OUR CLIENTS

500 N Michigan Ave, Suite 600, Chicago, Illinois 60611, UNITED STATES
+18882123539
sales@reportocean.com